GLP-1s sit at the rare intersection of unmet medical need, proven efficacy, and explosive demand Conditions investors chronically over-estimate or under-estimate based on the past few quarters growth trends
Most people start noticing a visible glow and improved skin texture after 3 to 5 sessions
Quantitative comparison of C-X-C chemokines produced by endotoxin-stimulated human alveolar macrophages
If the observed benefit of GLP-1 receptor agonists disappears or weakens meaningfully when compared with another contemporary metabolic therapy, then the story becomes less about a unique anticancer effect and more about broader metabolic optimization, comparator selection, or residual differences between treatment populations
People who qualify for GLP 1 therapy often already carry pancreatitis risk factors (gallstones, high triglycerides, obesity, alcohol, diabetes)